Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy of Ixekizumab Alone or Combined with Tirzepatide in Psoriasis Patients with Overweight or Obesity: A Phase 3b Study

  • By

  • Mark Lebwohl

  • Andrew Blauvelt

  • Cynthia E. Kartman

  • Cianna Leatherwood

  • Kenneth B. Gordon

  • Naveed Sattar

  • Luis Puig

  • Joseph F. Merola

  • Kimberly Siu

  • Rona Wang

  • Luna Sun

  • Ann Leung

  • Najwa Somani

  • Maria Jose Rueda

  • Anabela Cardoso

  • Mark C. Genovese

  • April W. Armstrong

  • Bruce Strober

  • July 1, 2026

Share

Original Source(s)

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b

  • by Mark Lebwohl, Andrew Blauvelt, Cynthia E. Kartman, Cianna Leatherwood, Kenneth B. Gordon, Naveed Sattar, Luis Puig, Joseph F. Merola, Kimberly Siu, Rona Wang, Luna Sun, Ann Leung, Najwa Somani, Maria Jose Rueda, Anabela Cardoso, Mark C. Genovese, April W. Armstrong, Bruce Strober

  • July 1, 2026

Related Content

Psoriasis–AD Switching May Mimic Treatment Failure

Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.

Case Report: Paradoxical psoriasis under TNF-α blockade may represent generalized abscessing staphyloderma – GASD syndrome by TNF antagonists

Informatics-Based Psychotherapeutic and Psychiatric Interventions in Dermatology: Scoping Review of Impacts on Skin Disease Severity and Mental Health Outcomes